Boston Scientific

Boston Scientific
VN:F [1.9.22_1171]
Rating: 0.0/5 (0 votes cast)

Boston Scientific is a leading innovator of medical solutions that improve the health of patients around the world. With 24,000 employees worldwide, sales force in 40+ countries, and 15 manufacturing facilities worldwide, the company invested $895 million in R&D in 2011, with a $7.6 billion revenue.  Continue reading «Boston Scientific»

Website Share Login to Edit

Full Description

Boston Scientific is a leading innovator of medical solutions that improve the health of patients around the world. With 24,000 employees worldwide, sales force in 40+ countries, and 15 manufacturing facilities worldwide, the company invested $895 million in R&D in 2011, with a $7.6 billion revenue.

 

rel="nofollow"

Address

Boston Scientific Corporate Headquarters One Boston Scientific Place Natick, MA 01760-1537, USA

Phone

+1 (508) 650-8000

Twitter username

https://twitter.com/bostonsci


Company News

  • Boston Scientific Announces Scheduled Presentations At Digestive Disease Week 2018

    MARLBOROUGH, Mass., June 1, 2018 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced key data that will be presented at Digestive Disease Week (DDW) being held in Washington D.C., June 2 to June 5. The annual meeting is the largest gathering of medical professionals and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Scheduled presentations of interest include an oral presentation of five-year outcomes after placement of a single WallFlex™ RX Fully Covered Stent System RMV for the treatment of patients with benign strictures due to chronic pancreatitis.1 A second oral presentation will discuss the use of the WallFlex™ RX Fully C...
  • Boston Scientific Announces Schedule of Presentations at EuroPCR 2018

    MARLBOROUGH, Mass., May 16, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of key presentations, including two late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program, in Paris, on May 22-25. During the late-breaking sessions on Wednesday, May 23, data from the RESPOND trial will provide two-year, 'real world' outcomes in patients treated with the LOTUS™ Transcatheter Aortic Valve System* as well as one-year results with the Agent™ Paclitaxel-Coated PTCA Balloon** from a multicenter study of two drug-coated balloons in patients with arterial in-stent restenosis. Other presentations of interest include ...
  • Boston Scientific To Participate In 34th Annual Strategic decisions Conference

    MARLBOROUGH, Mass., May 14, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 34th Annual Strategic Decisions Conference on May 31, 2018 in New York. Mike Mahoney, chairman and chief executive officer, will participate in a 50-minute presentation and question-and-answer session with the host analyst beginning at approximately 8:00 a.m. EDT. A live webcast of the presentation and question-and-answer session will be available on the Investor Relations section of the Boston Scientific website at www.bostonscientific.com/investors. A replay of the webcast will be accessible at www.bostonscientific.com/investo...
  • Boston Scientific Announces Real-World Data Demonstrating Success Of SMART Pass On The S-ICD System

    Late-Breaker Data Highlight Reduction in Rate of Inappropriate Shocks with Sensing Filter MARLBOROUGH, Mass., May 11, 2018 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced results from an analysis of the LATITUDE database which evaluated the successful reduction of inappropriate shocks using the SMART Pass sensing filter in patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. The real-world data were presented during a late-breaking clinical trial at Heart Rhythm 2018, the Heart Rhythm Society's 39th Annual Scientific Sessions in Boston, and demonstrated that when the sensing filter was in use, the rate of inappropriate shocks was reduc...
  • Boston Scientific To Participate In Bank of America Merrill Lynch 2018 Health Care Conference

    MARLBOROUGH, Mass., May 7, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2018 Health Care Conference on May 16, 2018 in Las Vegas. Dan Brennan, executive vice president and chief financial officer, and Susie Lisa, vice president, Investor Relations, will participate in a 30-minute question-and-answer session with the host analyst beginning at approximately 8:00 a.m. A live webcast of the question-and-answer session will be available on the Investor Relations section of the Boston Scientific website at www.bostonscientific.com/investors. A replay of the webcast will be acc...
  • Boston Scientific Closes NxThera Acquisition

    MARLBOROUGH, Mass., April 30, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of NxThera. The company developed the Rezūm® system, a minimally invasive therapy (MIT) for patients with symptomatic benign prostatic hyperplasia (BPH). With the completion of the acquisition, NxThera will become part of the Boston Scientific Urology and Pelvic Health business. "We are confident in the potential for this system to help patients with BPH and increase the number of men choosing MITs, because it offers long-term relief from symptoms without the side effects of medications," said Dave Pierce, executive vi...
  • Boston Scientific Announces Results For First Quarter 2018

    MARLBOROUGH, Mass., April 25, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.379 billion during the first quarter ended March 31, 2018. This represents growth of 10.1 percent on a reported basis, 6.2 percent on an operational1 basis and 5.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP earnings of $298 million or $0.21 per share (EPS), compared to GAAP earnings of $290 million or $0.21 per share a year ago, and achieved adjusted earnings per share of $0.33 for the period, compared to $0.29 a year ago. "Our consistently strong performance reflects our team's ongoing ded...